Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.

Journal for immunotherapy of cancer - 1 Apr 2021

Manzanares-Martin Barbara, Cebrián Aranda Arancha, Del Puerto-Nevado Laura, González Rafael, Solanes Sonia, Gómez-España Maria Auxiliadora, García-Foncillas Jesús, Aranda Enrique

Abstract excerpt

AIM: Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell immunoglobulin-like receptor) genotyping can provide a significant added value in the clinical outcome of patients with KRAS mutant mCRC based on cetuximab treatment. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Neoplasm Metastasis

Share to Patient Selection

Share to Progression-Free Survival

Share to Receptors, KIR

Source

Open in PubMed Open full text

Identifiers

PMID: 33833048
DOI: 10.1136/jitc-2020-001705
PMCID: PMC8039212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.PMID 33833048Read ↗

Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?Semantic proximity Read ↗

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.Semantic proximity Read ↗

[Relationship between Polymorphisms and the Efficacy of Cetuximab].Semantic proximity Read ↗

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.Semantic proximity Read ↗

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.Semantic proximity Read ↗

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.Semantic proximity Read ↗

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.Semantic proximity Read ↗

Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.